Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals is maximizing its potential for growth through strategic acquisitions and partnerships, such as the recent addition of XOMA. Despite lower-than-expected Q1/26 results, the company remains on track to meet its long-term revenue and earnings targets, as reaffirmed in its guidance. Additionally, LGND's focus on sustainability and responsible investments sets it apart as a socially responsible and forward-thinking company.

Ligand Pharmaceuticals is facing several key risks that contribute to its negative outlook. These include the high likelihood of a slowdown or decline in revenue from key royalty contributors, reliance on Captisol revenues, potential challenges with integrating strategic acquisitions, and the inherent risks associated with drugs in development. The company's financials also raise concerns, including a convertible loan with $460 million in outstanding principal and a recent $739 million equity acquisition. In addition, tax liabilities from a previous distribution/merger and uncertainty surrounding the success of future acquisitions and drug development adds to the downside risks for Ligand Pharmaceuticals.